Abstract
Candesartan is a drug from the group of AT1-receptor antagonists (sartans). Its efficacy in the therapy of cardiovascular diseases has been sufficiently proven in a number of preclinical, but most notably randomised clinical trials and meta-analyses that confirmed its benefit in the therapy of essential hypertension (most significantly in the post hoc analysis of the SCOPE trial) and chronic cardiac failure (particularly in the CHARM programme).